The 70 kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubuledamaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration-and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6K , paclitaxel inactivates this kinase in a concentration-and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca ++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxelinduced p70S6K inactivation. Moreover, the paclitaxelinduced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6K T421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6K T421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.
The 70 kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubuledamaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration-and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6K T421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca ++ , PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6K T421/S424 , paclitaxel inactivates this kinase in a concentration-and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca ++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxelinduced p70S6K inactivation. Moreover, the paclitaxelinduced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6K T421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6K T421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that
Introduction
The 70 kDa ribosomal S6 kinase (p70S6K) is a mitogenactivated serine/threonine kinase that plays a critical role in cell growth and survival (Grammer et al., 1996; Avruch et al., 2001; Harada et al., 2001; Templeton, 2001; Volarevic and Thomas, 2001 ). It appears that there are at least three mechanisms by which p70S6K regulates cell growth. First, p70S6K is a regulator of protein synthesis. p70S6K phosphorylates the 40S ribosomal protein S6 and leads to an increase in the rate of translation of the class of 5 0 TOP mRNA transcripts, which encode critical components of the cellular translational apparatus, thus facilitating an increase in the overall rate of protein translation (Jefferies et al., 1997; Thomas, 2000) . Second, p70S6K is a regulator of the cell cycle. Impairment of p70S6K by injection of neutralizing antibodies into fibroblasts arrests cells in G1 (Lane et al., 1993) . Inhibition of p70S6K with rapamycin, which depresses p70S6K activation by inhibiting the mammalian target of rapamycin (mTOR) kinase, blocks cell cycle progression through G1 (Chung et al., 1992; Price et al., 1992) . Cell cycle progression involves not only an increase in protein synthesis but also the coordinated activation of cyclins, cyclin-dependent kinase (CDK), and CDK inhibitors. Indeed, p70S6K has been shown to regulate cyclin D1 (Hashemolhosseini et al., 1998) and p27 Kip1 (Luo et al., 1996) . Finally, p70S6K is a regulator of cell size. p70S6K-deficient Drosophila and p70S6K knockout mice show a significant reduction in body size (Shima et al., 1998; Montagne et al., 1999) . Control of cell size appears to be consistent with a function of p70S6K in protein synthesis, but other mechanisms may contribute to cell size control. p70S6K has recently been reported to regulate survival signals through phosphorylation and inactivation of a proapoptotic molecule, BAD (Harada et al., 2001) . Growth factors such as insulin-like growth factor 1 do not induce phosphorylation at Ser-136 of BAD in p70S6K-deficient embryonic stem cells (Harada et al., 2001) . Therefore, inhibition of apoptosis and promotion of passage through the G1-S phase of the cell cycle suggest that p70S6K is an important and powerful regulator of cell proliferation and survival.
Regulation of p70S6K activity is complex. In general, phosphorylation of p70S6K has been associated with activation of kinase activity. As described in several review articles (Grammer et al., 1996; Avruch et al., 2001; Templeton, 2001; Volarevic and Thomas, 2001) , activation of p70S6K is tightly regulated by the coordinated phosphorylation of at least seven different serine and threonine residues. Four proline-directed sites have been identified in the autoinhibitory domain at the C-terminus of the protein (Ser ). These residues are rapidly phosphorylated in response to mitogenic stimuli. Additionally, there are three more critical residues: Thr 229 in the catalytic loop and Ser
371
, Thr 389 in the linker region (Grammer et al., 1996; Avruch et al., 2001; Volarevic and Thomas, 2001) . According to one model, the first step for p70S6K to be activated is the phosphorylation of four serine and threonine residues lying within the pseudosubstrate domain by proline-directed kinases that remain to be identified. This action releases the catalytic domain from the C-terminal autoinhibitory domain and permits subsequent Thr 389 phosphorylation by the 3-phosphoinositide-dependent protein kinase (PDK1), mTOR, and NIMA (never in mitosis, gene A)-related kinase-6/7 (NEK6/7) kinases, further facilitating Thr 229 access to PDK1 Templeton, 2001; Volarevic and Thomas, 2001 ). Phosphorylation of the four serine and threonine residues lying within the pseudosubstrate domain contributes to, but is not sufficient for, p70S6K activation. There is no report, however, to indicate whether phosphorylation of any of these four serine and threonine residues lying within the pseudosubstrate domain might link to p70S6K inactivation.
Paclitaxel is a common chemotherapeutic agent specifically targeting microtubules (Schiff & Horwitz, 1980; Horwitz, 1992) . The effect of paclitaxel on p70S6K has not been previously studied in depth. Here we have observed for the first time that paclitaxel, a nonmitogenic stimulus, induced intense phosphorylation of p70S6K at threonine 421 (T421) and serine 424 (S424) (p70S6K T421/S424 ). Phosphorylation of p70S6K T421/S424 induced by paclitaxel was, however, concurrent with inactivation of the enzyme in mitotic cells. Phosphorylation of p70S6K T421/S424 and inactivation induced by paclitaxel were found to be regulated by multiple and different signaling pathways.
Results
Paclitaxel induces phosphorylation of p70S6K at T421 and S424 in a time-and concentration-dependent manner Paclitaxel is a chemotherapeutic drug frequently used in the treatment of patients with breast and ovarian cancers. Paclitaxel inhibits tumor growth by stabilizing microtubules and inhibiting formation of mitotic spindles and arresting cell growth at the G2/M phase of cell cycle (Schiff & Horwitz, 1980) . In agreement with previous reports (Schiff & Horwitz, 1980; Horwitz, 1992) , paclitaxel arrested growth of SKBr3 breast cancer cells in G2/M and induced apoptosis (Figure 1a) . While investigating signaling pathways induced by treatment of SKBr3 cells with paclitaxel, we found that paclitaxel inhibited the serine/threonine phosphorylation of ERK MAP kinase, p38 MAP kinase, and AKT kinase (Figure 1b) . By contrast, paclitaxel promoted phosphorylation of JNK and p70S6K T421/S424 as illustrated by phospho-specific antibodies (Figure 1b ). Paclitaxel induced a 12.5-fold increase in phosphorylation of p70S6K at T421 and S424 ( Figure 1c ). As shown in Figure 2a and b, paclitaxel was capable of inducing p70S6K T421/S424 phosphorylation in a time-and dosagedependent manner in SKBr3 cells. The second generation of paclitaxel, docetaxel (DTX), and a water-soluble form of paclitaxel, poly(l-glutamic acid)-paclitaxel conjugate (PG-TAX), were also able to induce robust p70S6K T421/S424 phosphorylation ( Figure 2c ). Paclitaxel also induced p70S6K T421/S424 phosphorylation in another breast cancer cell line, BT474, and two ovarian cancer cell lines, SKOv3 and 2008 (Figure 2d ), indicating that paclitaxel-induced p70S6K T421/S424 phosphorylation is not cell-type-specific event.
To confirm the ability of paclitaxel to induce phosphorylation of p70S6K T421/S424 and to determine which amino-acid residues were phosphorylated by paclitaxel, phosphoamino-acid analysis was performed. As shown in Figure 3a , paclitaxel treatment induced p70S6K phosphorylation at serine and theronine residues. Antiphosphoserine and antiphosphothreonine antibodies further confirmed these results. Both threonine and serine were phosphorylated after paclitaxel treatment, whereas there was no detectable tyrosine phosphorylation (Figure 3b ).
Paclitaxel does not induce phosphorylation of p70S6K at T389 and S411 residues Some eight phosphorylation sites within p70S6K are currently believed to mediate kinase activation in a hierarchical fashion Volarevic and Thomas, 2001 ). Phosphorylation of T421 and S424 situated within a pseudo-substrate autoinhibitory domain in the carboxyterminal noncatalytic tail is believed to be one of the initial steps in p70S6K activation Volarevic and Thomas, 2001) . Based on the availability of phospho-p70S6K antibodies, we have also assessed the phosphorylation of p70S6K at T389 and S411 residues after paclitaxel treatment in multiple breast and ovarian cancer cell lines. As shown in Figure 3c , no phosphorylation of p70S6K T389 was found in each of the four cell lines after paclitaxel treatment. Only a slight increase in phosphorylation of p70S6K S411 was observed in SKOv3, SKBr3, and BT474 cells, whereas significant phosphorylation of p70S6K T421/S424 was observed after paclitaxel treatment (Figure 3c ). It is well known that at least seven regulatory sites specific for serine/threonine phosphorylation within p70S6K control its activity (Grammer et al., 1996; Avruch et al., 2001; Templeton, 2001; Volarevic and Thomas, 2001 ). The first step in p70S6K activation is the phosphorylation of the serine/threonine-proline sites including T421 and S424 in the autoinhibitory domain Volarevic and Thomas, 2001 ). Therefore, we investigated the effect of paclitaxel on total p70S6K activity and found that paclitaxel suppressed p70S6K activity in a dose-dependent ( Figure 4a ) and time-dependent (Figure 9b ) manner. The activity bottomed 16 h after paclitaxel treatment (Figure 4b ), when 6% of cells were undergoing apoptosis and 55% of cells were at the G2/M phase. Furthermore, we have extended this study to another breast cancer cell line, BT474 (Figure 4c ), and two ovarian cancer cell lines, 2008 ( Figure 4d ) and SKOV3 (Figure 4e ). Similar results were observed in each cell line after paclitaxel treatment. The reduction in p70S6K activity in paclitaxel-treated cells was not because of a decrease in total p70S6K abundance evidenced by Western blot analysis as shown in Figure 4 . Thus, paclitaxel inactivates p70S6K despite phosphorylation of p70S6K T421/S424 . These data further confirm that phosphorylation of p70S6K T421/S424 is not necessarily concordant with activation of p70S6K.
U n t r e a t e d P a c l i t a x e l ← Original P-labeled p70S6K protein with 6 n hydrochloric acid was performed for 1.5 h at 1101C, and the radioactive phosphoamino-acid composition was determined by TLC plates. Encircled areas indicate the locations of phosphoserine (p-Ser), phosphothreonine (p-Thr), and phosphotyrosine (p-Tyr), visualized by ninhydrin staining. The results were representative of two independent experiments. (b) Western blot analysis with antiserine, threonine, and tyrosine antibodies. SKBr3 cells were treated with paclitaxel as described above. Total lysates were isolated and immunoprecipitated with antitotal p70S6K antibody. The immunoprecipitates were resolved on 8% SDS-PAGE. Western blotting was performed with antiserine antibody. Then the same blot was stripped and reprobed with antithreonine, tyrosine, and total p70S6K antibodies. The above results were representative of two independent experiments. (c) No significant P-p70S6K T389 and P-p70S6K S411 after paclitaxel treatment. SKBr3, BT474, 2008 , and SKOv3 cells cultured in complete medium were treated with paclitaxel at 20 nm for 24 h. Cells were then harvested, protein isolated, and Western blot analysis performed as described in Experimental procedures. The same blot was stripped and reprobed with three antiphospho-p70S6K antibodies and a pan-anti-p70S6K antibody. These results were representative of two independent experiments p70S6K T421/S424 phosphorylation requires both de novo RNA and protein synthesis To determine whether transcription or protein synthesis is required for paclitaxel-induced phosphorylation of p70S6K T421/S424 in SKBr3 cells, the effects of a transcriptional inhibitor actinomycin D (AD) and a protein synthesis inhibitor cyclohexamide (CHX) were analysed. As shown in Figure 5 , AD completely abolished paclitaxel-induced p70S6K T421/S424 phosphorylation even at a concentration of 0.1 mg/ml (lanes 7-10), demonstrating a requirement of transcription for paclitaxelinduced p70S6K phosphorylation. Similarly, CHX suppressed paclitaxel-upregulated p70S6K phosphorylation at concentrations of 10 and 5 mg/ml ( Figure 5 , lanes 3-6). Thus, protein synthesis is also required for phosphorylation of p70S6K T421/S424 after paclitaxel treatment. . Cells were harvested and subjected to total protein isolation and immunoprecipitation with a pan-p70S6K antibody. A kinase assay specific for p70S6K was then performed as described in Experimental procedures. (a) Paclitaxel inactivates p70S6K in a dose-dependent manner. SKBr3 cells were treated with paclitaxel for 24 h at the indicated concentration and total protein was prepared and subjected to p70S6K kinase assay. *, Po0.05 compared with untreated group; **, Po0.01 compared with untreated group. (b) Paclitaxel inactivates p70S6K in a time-dependent manner. SKBr3 cells were treated with paclitaxel at 100 nm for indicated time points and total protein was prepared and subjected to p70S6K kinase assay. *, Po0.05 compared with untreated group; **, Po0.01 compared with untreated group. (c) Paclitaxel inactivates p70S6K in BT474 breast cancer cells. BT474 cells were treated with paclitaxel at 100 nm for 24 h and total protein was prepared and subjected to p70S6K kinase assay. **, Po0.01 compared with untreated group. (d) Paclitaxel inactivates p70S6K in 2008 ovarian cancer cells. In all, 2008 cells were treated with paclitaxel at 100 nm for 24 h and total protein was prepared and subjected to p70S6K kinase assay. **, Po0.01 compared with untreated group. (e) Paclitaxel inactivates p70S6K in SKOv3 ovarian cancer cells. SKOv3 cells were treated with paclitaxel at 100 nm for 24 h and total protein was prepared and subjected to p70S6K kinase assay. *, Po0.05 compared with untreated group. These results were confirmed in three independent experiments
Effect of inhibition of ERK1/2, p38 MAP kinase, and JNK on paclitaxel-indued p70S6K
phosphorylation Although Ras/MAP kinase pathways are not the major upstream regulators of p70S6K, MAP kinases can phosphorylate p70S6K in vitro (Mukhopadhayay et al., 1992; Grammer et al., 1996) . To investigate whether activity of MAP kinase components (ERK1/2, p38, and JNK pathways) is necessary for paclitaxel to induce p70S6K T421/S424 phosphorylation, SKBr3 cells were incubated with several selective MAP kinase inhibitors prior to treatment with paclitaxel. PD98059 (Figure 6a , lanes 3-4) and PD184352 (Figure 6a , lanes 5-6), which prevent the activation of MEK1 (and hence the activation of ERK1/2), decreased paclitaxel-stimulated p70S6K phosphorylation. The efficacy of PD98059 and PD184352 was confirmed by antiphospho-ERK antibody (Figure 6b ). Paclitaxel-stimulated phosphorylation of p70S6K was not affected by SB203580, a specific p38 MAP kinase inhibitor, or by SB202190 that selectively inhibits p38 MAP kinase at low concentration (3 mm) (Figure 6c, lanes 3-6) . The efficacy of SB203580 and SB202190 was confirmed by antiphospho-p38 antibody (Figure 6d ). However, SP600125, a selective inhibitor of JNK activity (Bennett et al., 2001) , blocked paclitaxelstimulated p70S6K phosphorylation (Figure 6e ). The efficacy of SP600125 was confirmed by antiphospho-JNK antibody (Figure 6f ). These results indicated that paclitaxel-induced p70S6K T421/S424 phosphorylation in SKBr3 cells may involve MEK1 and JNK activity, but does not require p38 MAP kinase activity.
ERK1/2 inhibitors (PD98059 and PD184352) and p38 inhibitor SB203580 did not significantly affect p70S6K basal activity, whereas JNK inhibitor SP600125 stimulated p70S6K basal activity (Figure 7) . Inhibition of both ERK and p38 MAP kinases could not alter paclitaxel-induced p70S6K inactivation (Figure 7) , which suggested that with or without p70S6K T421/S424 phosphorylation, paclitaxel was able to inactivate the kinase. However, inhibition of JNK prevented paclitaxel-induced p70S6K inactivation (Figure 7) , which indicated that JNK activity was required for paclitaxel to inactivate p70S6K.
Effect of inhibition of protein kinase C (PKC), intracellular calcium (Ca ++ ), and phospholipid Cg (PLCg) pathway on paclitaxel-indued p70S6K T421/S424 phosphorylation Since PKC (Romanelli et al., 1999) , Ca ++ (Conus et al., 1998) , and their upstream regulator PLCg (Grammer et al., 1996) have been linked to p70S6K phosphorylation and activity, it was of interest to investigate whether PLCg-PKC-Ca ++ signaling pathways were involved in the phosphorylation of p70S6K T421/S424 elicited by paclitaxel. Two pan-PKC inhibitors (GF109203X and RO318425), two Ca ++ chelators (MAPTAM and BAPTA/AM), and one PLCg (U73122) were employed. As shown in Figure 8a , both pan-PKC inhibitors diminished paclitaxel-induced p70S6K T421/S424 phosphorylation. Similarly, both Ca ++ chelators decreased or abrogated paclitaxel-induced p70S6K T421/S424 phosphorylation (Figure 8b ). Consistent with the above observations, the inhibitor of PLCg, U73122, abolished paclitaxel-induced p70S6K T421/S424 phosphorylation ( Figure 8c ). These results suggest that PKC and Ca ++ signaling pathways are involved in the phosphorylation of p70S6K T421/S424 induced by paclitaxel. Ca ++ chelator MAPTAM suppressed p70S6K activity, whereas PKC inhibitor GF109203X stimulated p70S6K activity (Figure 8d ). These results indicated that PKCs and calcium signaling differentially regulated p70S6K activity, although both were implicated in paclitaxel-induced p70S6K T421/S424 phosphorylation. Ca ++ chelator MAPTAM had no dramatically synergistic effect on p70S6K inactivation with paclitaxel ( Figure 8d ). PKC inhibitor GF109203X prevented paclitaxel-induced p70S6K inactivation (Figure 8d ), which indicated that PKC activity was required for paclitaxel to inactivate p70S6K.
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Figure 5 Paclitaxel-induced phosphorylation of p70S6K T421/S424 requires both de novo RNA and protein synthesis. SKBr3 cells were first pretreated with cycloheximide (CHX) at two concentrations (10 and 5 mg/ml) or with actinomycin D (AD) at two concentrations (1 and 0.1 mg/ml) for 2 h in complete medium. The cells were then treated with paclitaxel at 20 nm for 24 h. Cells were harvested and subjected to total protein isolation and Western blot analysis with anti-P-p70S6K T421/S424 and anti-b actin antibodies. These results were representative of three independent experiments Effect of inhibition of PI3K and mTOR/FRAP/RAFT pathways on paclitaxel-indued p70S6K T421/S424 phosphorylation PI3K and mTOR/FRAP/RAFT are believed to be the major upstream effectors of p70S6K (Grammer et al., 1996; Avruch et al., 2001; Templeton, 2001; Volarevic and Thomas, 2001 ). Therefore, their involvement in the induction of p70S6K T421/S424 phosphorylation was examined using selective PI3K inhibitors (LY294002 and wortmannin) and the mTOR kinase inhibitor, rapamycin. Cotreatment of the cells with paclitaxel and LY294002 or wortmannin resulted in decreased or absent p70S6K T421/S424 phosphorylation ( Figure 9a ). As expected, rapamycin also decreased paclitaxel-induced p70S6K T421/S424 phosphorylation (Figure 9b ). The inhibitor studies indicated that PI3K and mTOR were required for the induction of phosphorylation of p70S6K T421/S424 by paclitaxel. As expected, both rapamycin and LY294002 significantly suppressed p70S6K activity (Figure 9c) . No further decrease in p70S6K activity was observed in the combination with paclitaxel ( Figure 9c ).
Phosphorylation of p70S6K
T421/S424 and inactivation of p70S6K are associated with the mitotic cell fraction among paclitaxel-treated cells As mentioned above, paclitaxel induced significant G2/M arrest and apoptosis in SKBr3 cells, which resulted in two cell fractions: suspended and attached. We have used a shake-off technique as described in Experimental procedures to examine which cell fraction is responsible for the phosphorylation of p70S6K T421/S424 and inactivation of p70S6K after paclitaxel treatment. SKBr3 cells in 175-cm 2 culture flasks were treated with 100 nm paclitaxel for the indicated intervals and then gently shaken, permitting us to separate a detached (suspended) fraction and an attached fraction of cells. The cells from the two fractions at each time point were subjected to Giemsa staining and cell cycle analysis. Giemsa staining clearly showed that there are few mitoses Inhibition of JNK prevented paclitaxel-induced S6K inactivation, whereas inhibition of ERK and p38 MAP kinases could not. SKBr3 cells were first pretreated with individual inhibitors for 1 h in complete medium. The cells were then treated with paclitaxel at 20 nm for 24 h. A kinase assay specific for p70S6K was then performed as described in Experimental procedures. *, Po0.05 compared with untreated group. This experiment was repeated twice with similar results among untreated SKBr3 cells and that the majority of cells from the attached fraction at 24 h time point were not mitosis (data not shown). By contrast, the majority of detached cells were arrested in mitosis. Detached cells had a significantly higher mitotic index than did the cells from the attached fraction (data not shown). Correspondingly, cell cycle analysis showed that detached cells had a significantly higher G2/M component than did the attached fraction (data not shown). Interestingly, the attached cells that exhibited an increased G2/ M peak did not have higher mitotic indices. Thus, cells in the attached fractions were in early stage of G2 phase, but not in M phase. By contrast, the detached fractions that had an increased G2/M peak also had higher mitotic indices (data not shown), indicating that detached cells were in the M phase.
Paclitaxel -
As shown in Figure 10a , no significant phosphorylation of p70S6K T421/S424 was observed in the attached fractions. The p70S6K activity in the attached fractions decreased slightly and slowly within 24 h after paclitaxel treatment, but recovered completely (Figure 10b) . In sharp contrast, significant phosphorylation of p70S6K T421/S424 was observed in four detached fractions ( Figure 10c , lanes 2-5), and correlated with the mitotic index. After 32 h, the majority of cells in detached fractions were apoptotic cells that did not contain phosphorylated p70S6K T421/S424 (Figure 10c , lanes 6-8). The p70S6K activity in the detached fractions decreased dramatically within the first 16 h after paclitaxel treatment and reached a minimum at 16 h (Figure 10d ). p70S6K activity recovered slightly at later intervals, but did not return to control levels (Figure 10d) . A high level of cyclin B1 expression could be detectable in the detached fraction (Figure 10c) , consistent with the high fraction of mitotic cells in detached cells. Taken together, these data suggest that paclitaxel-induced phosphorylation of p70S6K T421/S424 and inactivation of p70S6K is associated with cells in mitosis.
Discussion
Phosphorylation of p70S6K in mammalian cells is often triggered by mitogenic stimuli such as growth factors, hormones, and amino acids Volarevic and Thomas, 2001) . Multiple sites of serine and threonine phosphorylation on p70S6K are believed to be essential to its activation. One current model for p70S6K activation suggests that upon mitogen stimulation, the four proline-directed sites at the C-terminus (Ser , and Thr 389 are phosphorylated. The final step in p70S6K activation involves phosphorylation of the Thr 229 on activation loop. (Grammer et al., 1996; Avruch et al., 2001; Templeton, 2001; Volarevic and Thomas, 2001) . Here, we have demonstrated for the first time that paclitaxel as a microtubule-damaging agent is able to induce phosphorylation of p70S6K T421/S424 . Paclitaxel-induced phosphorylation of p70S6K T421/S424 is concurrent with decreased activity of p70S6K. Our data show that inhibitors of mTOR, PI3K, and Ca ++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. These results not only confirm that phosphorylation of p70S6K T421/S424 is not always associated with activation of p70S6K, but also demonstrate that phosphorylation of p70S6K Paclitaxel-induced phosphorylation of p70S6K T421/S424 requires PI3K and mTOR/FRAP signaling pathways. SKBr3 cells were first pretreated with individual inhibitors for 1 h in complete medium. The cells were then treated with 20 nm paclitaxel for 24 h. Cells were harvested, total protein was isolated and resolved for Western blot analysis with anti-P-p70S6K T421/S424 and anti-b actin antibodies. (a) PI3K signaling is required. Two highly selective PI3K inhibitors LY294002 at 10 mm and wortmannin at 2 mm were used for pretreatment. (b) mTOR/FRAP signaling is required. MTOR-specific inhibitor rapamycin at 55 nm were used for pretreatment. (c) p70S6K kinase assay. SKBr3 cells were first pretreated with rapamycin or LY294002 for 1 h in complete medium. The cells were then treated with paclitaxel at 20 nm for 24 h. A kinase assay specific for p70S6K was then performed. *, Po0.05 compared with untreated group. This experiment was repeated twice with similar results and kinase inactivation induced by paclitaxel are regulated by different mechanisms.
The significance of paclitaxel-induced Thr 421 and Ser 424 phosphorylation of p70S6K is not known yet. Based on our data and that in the literature, Thr 421 and Ser 424 phosphorylation of p70S6K may or may not be important for inhibition of the enzyme. A mitosisrelated inhibitory protein, human prolyl isomerase Pin1, has been shown to inhibit G2/M progression by interacting with phospho-proteins, such as NIMA, Cdc25, and Wee1 (Zhou et al., 1999; Nakamura et al., 2001) . Interestingly, Pin1 is reported to interact with p70S6K (Yaffe et al., 1997) . Data in Figure 10 show that paclitaxel-induced phosphorylation and inactivation of p70S6K occur exclusively in mitotic cells. One possibility is that paclitaxel-induced phosphorylation of Thr 421 and Ser 424 of p70S6K could create docking sites for Pin1-like inhibitory factors, which can then bind and isomerize the phosphorylated Ser/Thr-Pro peptide bond. As a result of the binding of Pin-like inhibitory factor(s), the structure of p70S6K becomes changed and its activity suppressed. Indeed, Ser 411 of p70S6K, a close residue of Thr 421 and Ser
424
, has been shown to be phosphorylated by Cdc2-cyclin B complex in vivo, which may cause the inactivation of p70S6K during mitosis (Papst et al., 1998 . Inhibitors of mTOR, PI3K, and Ca ++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate activity. These results suggest that phosphorylation of p70S6K T421/S424 is not related to regulation of kinase activity. Our unpublished data indicated that conversion of residues Thr 421 and Ser 424 to Ala fails to decrease the basal level of p70S6K activity and to retard paclitaxelinduced inactivation of p70S6K. There are at least two reports, which indicate that mutation of four carboxylterminal phosphorylation sites has little or no effect on the activity of p70S6K (Edelmann et al., 1996; Mahalingam & Templeton, 1996) . Thus, the significance of paclitaxel-induced Thr 421 and Ser 424 phosphorylation of p70S6K remains to be elucidated. Probably, it may play a role in subsequent activation or inactivation steps.
Which kinase phosphorylates Thr 421 and Ser 424 of p70S6K in paclitaxel-treated cells is not clear. Autoinhibitory domain kinases have been proposed as candidates, including Cdc2 and the mitogen-activated kinase ERK1/2 MAP kinase (Mukhopadhayay et al., 1992) . ERK1/2 MAP kinase is unlikely the kinase to phosphorylate these two sites, since paclitaxel treatment inactivates ERK1/2 (Figure 1b) . Cdc2 (Cdk1) has been shown to phosphorylate p70S6K at Ser 411 in mitosis (Papst et al., 1998) . However, there is no significant phosphorylation of Ser 411 in paclitaxel-treated cells (Figure 3b ). Therefore, Cdc2 will not be a strong candidate. Other members of the proline-directed kinase family may phosphorylate these sites. p38 MAP kinase has been indicated to phosphorylate the C-terminus of p70S6K in vitro (Grammer et al., 1996) . However, inactivation of p38 kinase by paclitaxel treatment (Figure 1b) has made it unlikely. JNK may phosphorylate Thr 421 and Ser 424 (Grammer et al., 1996) . Given the upregulation of JNK phosphorylation in paclitaxeltreated cells (Figure 1b) , our data are consistent with this hypothesis. Additionally, our data show that paclitaxel-induced phosphorylation of p70S6K occurs exclusively in mitotic cells, suggesting that cells at cell cycle M phase contain protein kinase(s) that phosphorylate Thr 421 and Ser
. Another possibility is that paclitaxel may activate microtubule-related kinase(s) that phosphorylate Thr 421 and Ser
. Further studies are needed to address these questions.
In this study, we have identified several upstream signaling pathways required for paclitaxel-induced phosphorylation of p70S6K, which could be direct or indirect effects. Inhibition of JNK or ERK1/2 MAP kinase decreased paclitaxel-induced p70S6K T421/S424 phosphorylation ( Figure 5 ), consistent with previous reports that ERK1/2 MAP kinases can contribute to phosphorylation of serine/threonine sites at the Cterminal of p70S6K (Mukhopadhayay et al., 1992; Grammer et al., 1996) . JNK was stimulated by paclitaxel treatment as shown in Figure 1 , raising the possibility that JNK may also contribute to phosphorylation of p70S6K. Surprisingly, inhibition of p38 MAP kinase did not affect paclitaxel-induced phosphorylation.
Atypical PKCs, specifically PKCl and PKCz, have been shown to regulate p70S6K phosphorylation and activity (Akimoto et al., 1998; Romanelli et al., 1999) . Depletion of intracellular stores of Ca 2+ has been shown to abolish p70S6K activation, but has no effect on AKT activation (Conus et al., 1998) . In agreement with these reports, our data in Figure 6 demonstrate that PKC and Ca ++ signaling pathways were involved in the paclitaxel-induced phosphorylation of p70S6K T421/S424 . Inhibition of PLCg, the upstream regulator of PKC and Ca . p70S6K has been demonstrated to be a downstream effector of the PI3K signaling pathway (Chung et al., 1994; Ming et al., 1994; Reif et al., 1997) . PI3K inhibitors, wortmannin and LY294002, block the activation of p70S6K and constitutively active forms of PI3K activate p70S6K (Chung et al., 1994; Reif et al., 1997) . Phosphorylation of Thr 229 and Thr 389 can be inhibited by wortmannin, an inhibitor of PI3K activity (Ming et al., 1994) . Whereas PI3K does not appear to phosphorylate p70S6K directly, the generation of 3-phosphoinositide (3-PtdIns) products by PI3K and PDK1 are required for both Thr 229 and Thr 389 phosphorylation Balendran et al., 1999) . PDK1 has been shown to be the physiologic p70 Thr 229 kinase (Alessi et al., 1998; Pullen et al., 1998) . PDK1 is later confirmed to phosphorylate Thr 389 directly as well (Balendran et al., 1999) . PDK1 null embryonic stem cells lack IFG-1-stimulated phosphorylation of both Thr 229 and Thr 389 of p70S6K (Williams et al., 2000) . It was reported that the rate of decline in p70S6K activity after addition of wortmannin correlated more closely with the dephosphorylation of Thr 389 than of Thr 229 (Burnett et al., 1998; Isotani et al., 1999 ) and possibly to phosphorylate other p70S6K residues (Dennis et al., 1996) . Thr 389 phosphorylation is blocked by rapamycin . mTOR/FRAP may also control p70S6K phosphorylation and activity through protein phosphatase 2A (PP2A). PP2A has been shown to associate directly with and to dephosphorylate p70S6K (Peterson et al., 1999) . The mTOR/ FRAP kinase inhibits PP2A-mediated p70S6K dephosphorylation (Peterson et al., 1999) . Our data presented in Figure 7b support the requirement of the mTOR/ FRAP signaling pathway for p70S6K phosphorylation at Thr 421 and Ser 424 residues. This study has demonstrated that paclitaxel is able to decrease substantially p70S6K activity. As p70S6K is an important factor for cell growth and survival, paclitaxel may exert its antitumor effect in part via inhibition of p70S6K. Several factors could contribute to inactivation of p70S6K in paclitaxel-treated cells. One of the major upstream regulators of p70S6K, AKT, is inhibited by paclitaxel treatment (Figure 1b ). Avruch's lab has recently identified a never-in-mitosis/Aspergillus (NIMA) kinase, termed NIMA-related kinase (NEK) 6, as the kinase that physiologically phosphorylates Thr389 . The NIMA kinases associate with mitotic spindles, and phosphorylate the mitotic histone H3 (Ed Souza et al., 2000) , whereas paclitaxel targets microtubule directly (Schiff & Horwitz, 1980; Horwitz, 1992) . Thus, paclitaxel could directly affect the NIMA kinases including NEK6, preventing phosphorylation of Thr389. Indeed, our data in Figure 3b indicate that paclitaxel fails to phosphorylate Thr389 in spite of substantial phosphorylation of Thr 421 and Ser
. In summary, microtubule-damaging agent paclitaxel is able to induce p70S6K T421/S424 phosphorylation and decreases its activity simultaneously. Paclitaxel-induced p70S6K T421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca ++ , PI3K, and mTOR. However, these different signaling pathways regulate p70S6K activity differently. Inhibitors of mTOR, PI3K, and Ca ++ impair p70S6K activity and cannot further augment paclitaxel-induced p70S6K inactivation. Inhibitors of JNK and PKC stimulate activity and prevent paclitaxel-induced p70S6K inactivation. Inhibitors of ERK and p38 (that has no effect on p70S6K T421/S424 phosphorylation) MAP kinases have no effect on p70S6K activity and cannot prevent paclitaxel-induced p70S6K inactivation. Moreover, paclitaxel-induced phosphorylation and low activity of p70S6K occur only in mitotic cells. Our data suggest that paclitaxel-induced p70S6K T421/S424 phosphorylation and inactivation are differentially regulated. Paclitaxel may exert its antitumor effect in part via inhibition of p70S6K.
Materials and methods

Cell culture
The human breast cancer cell lines SKBr3 and BT474, and human ovarian cancer cell line SKOv3 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The human ovarian cancer cell line 2008 was obtained from Dr Zahid Siddik at the Department of Experimental Therapeutics, MD Anderson Cancer Center. SKBr3 was grown in complete medium containing RPMI 1640 (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA), 2 mm l-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in humidified air with 5% CO 2 at 37 o C. BT474 and 2008 cells were grown in complete medium containing DMEM (GIBCO, Grand Island, NY, USA), supplemented with 10% FBS, 2 mm l-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. SKOv3 cells were maintained in McCoy 5A medium containing 10% FBS, 2 mm l-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. For all experiments, cells were detached with 0.25% trypsin-0.02% EDTA. For cell culture, 5 Â 10 5 exponentially growing cells were plated into 100-mm tissue culture dishes or 75-175-cm 2 culture flasks. After culture for 24 h in complete medium, cells were treated (if applicable) with or without paclitaxel for the desired period in the presence or absence of either the PLCg-specific inhibitor U73122 (4 mm), the Ca ++ chelators MAPTAM (20 mm) and BAPTA/AM (25 mm), the pan-PKC inhibitors Ro318425 (2.5 nm) and GF109203 (5 mm), the PI3K inhibitors LY294002 (10 mm) or wortmannin (2 mm), the ERK1/2 MAP kinase inhibitor PD98059 (50 mm) and PD184352 (50 nm), the p38 MAP kinase inhibitor SB203580 (2 mm) and SB202190 (3 mm), JNK inhibitor SP600125 (10 mM), or the FRAP/mTOR inhibitor rapamycin (55 nm) in complete medium.
Reagents
Paclitaxel and Giemsa were purchased from Sigma (St Louis, MO, USA). DTX was obtained from Aventis Pharmaceuticals (Collegeville, PA, USA). A water-soluble PG-TAX was made according to previous report (Li et al. (1998) , also available from Cell Therapeutics, Inc., Seattle as Xyotax). Chemical inhibitors U73122, LY294002, GF109203, the Ca ++ chelators MAPTAM and BAPTA/AM, and PD98059 were purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA, USA). MEK1-specific inhibitor PD184352 (2-[2-chloro-4-iodo-phenylamino]-N-cyclopropylmethoxy-3, 4-difluoro-benzamide), wortmannin, SB203580, Ro318425, SP600125, and rapamycin were obtained from CalbiochemNovabiochem Corp. (La Jolla, CA, USA). Antibodies to phospho-JNK, total JNK, and pan-p70S6K were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies to phospho-p38, phospho-AKT, phosphop70S6K 
Preparation of total protein and western immunoblot analysis
The procedures for the preparation of total protein and Western immunoblot analysis were performed as described previously (Le et al., 2001) .
Cell cycle analysis
Cell cycle distribution was analysed by flow cytometry. The treated cells were trypsinized, washed once with PBS, and fixed overnight in 70% ethanol. Fixed cells were centrifuged at 300 g for 10 min and washed with PBS. Cell pellets were resuspended in PBS containing 50 mg/ml of RNase A and 50 mg/ml propidium iodide and incubated for 20 min at 371C with gentle shaking. Stained cells were filtered through nylon mesh (41 mm) and analysed on a Coulter flow cytometer XL-MCL (Coulter Corporation, Miami, FL, USA) for relative DNA content based on red fluorescence levels. Doublets and cell debris were excluded from the DNA histograms. The percentages of sub-G1 cell population were determined based on relative DNA content. The percentages of cells in different cell cycle compartments were determined using the MULTI-CYCLE software program (Phoenix Flow Systems, San Diego, CA, USA).
Phosphoamino-acid analysis
Immunoprecipitated p70S6K from 32 P-labeled SKBr3 cells was separated by SDS-PAGE and transferred to a PVDF membrane (Immobilon-P, Millipore). The portion containing phosphorylated p70S6K was excised after autoradiography, and the membrane was washed 5 times with deionized water. The analysis was performed as described in our previous report (Le et al., 1999) , with some modification. For phosphoamino-acid analysis, the p70S6K on Immobilon-P (Millipore) was incubated in 200 ml of 6 n HCl (Pierce) at 1101C for 90 min. After evaporation of HCl, the samples were mixed with phosphoamino-acid standard (1 mg each of cold phosphoserine, phosphothreonine, and phosphotyrosine (Sigma)) in pH 1.9 buffer (H 2 O/88% formic acid/glacial acetic acid, 897 : 25 : 78), and the mixtures were applied to a thinlayer chromatography (TLC) plate (JT Baker) and separated with an HTLE-7000 electrophoresis system (CBS, Del Mar, CA, USA). Electrophoresis was carried out in pH 1.9 buffer at 1500 V for 45 min for the one-dimension separation. Positions of phosphoamino acids were determined by ninhydrin (0.25% in acetone) staining.
Metabolic labeling and immunoprecipitation
SKBr3 cells (1 Â 10 7 ) were incubated in phosphate-free RPMI 1640 medium containing 10% dialyzed-FBS and treated with 20 nm paclitaxel for 24 h, followed by the addition of [ 32 P]orthophosphate at 2 mCi/ml. After 4 h of labeling, cells were washed with phosphate-free medium twice and lysed in radioimmunoprecipitation assay (RIPA) buffer (20 mm Tris (pH 7.5), 150 mm NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 2 mm EDTA, 1 mm EGTA) with proteinase inhibitors (1 mm PMSF, 2 mg of aprotinin per ml, and 2 mg of leupeptin per ml) and phosphatase inhibitors (50 mm NaF and 1 mm sodium orthovanadate). The lysate was spun at 14 000 g, and the supernatant was cleared with protein A beads for 30 min, followed by incubation with anti-p70S6K antibody at 41C for 1.5 h. The immune complex was captured with protein A beads for 1 h, washed with RIPA buffer four times, resuspended in loading buffer, and separated by SDS-PAGE. The separated samples were transferred to a membrane and visualized by autoradiography. p70S6K activity assay p70S6K activity was measured by an immune complex kinase assay using an S6 peptide, RRRLSSLRA, as a substrate (Santa Cruz). Briefly, total cell lysates were prepared from SKBr3, BT474, 2008, or SKOv3 cells treated with diluent or paclitaxel 100 nm. Cells were harvested at the times indicated and lysed in 300 ml of buffer A containing 20 mm Tris (pH 7.5), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% (v/v) Triton X-100, 2.5 mm sodium pyrophosphate, 1 mm glycerol phosphate, 1 mm Na 3 VO 4 , 1mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mm phenylmethylsulfonyl fluoride. The cell lysates were clarified by centrifugation at 10 000 g for 10 min at 41C. The supernatant fractions containing equal amounts of proteins were incubated with a pan-p70S6K antibody at 41C for 1.5 h and then for an additional 1.5 h with protein A-Sepharose beads (Santa Cruz). After washing four times with PBS, the immunoprecipitates were incubated at 301C for 30 min in a mixture of the following: 20 ml of assay dilution buffer (20 mm MOPS, pH 7.2, 25 mm glycerol phosphate, 5 mm EGTA, 1 mm Na 3 VO 4 , and 1 mm DTT), 10 ml of substrate mixture (S6 peptide in assay dilution buffer), 10 ml of PNPP solution, and 10 ml of [g-32 P]ATP (1 mCi/ml, Amersham). After a brief spin, each sample was spotted onto numbered P81 paper circles (Whatman) and washed three times (10 min each) with 2% phosphoric acid and once (10 min) with acetone. Each sample paper was transferred into a scintillation vial containing 5 ml of scintillation fluid and then counted in a liquid scintillation counter. At the same time, immunoprecipitates isolated by nonimmune IgG serum (Santa Cruz) instead of the p70S6K antibody were used as background controls. The actual p70S6K kinase activity (in cpm) from each sample was corrected for background. Each sample was tested in duplicate.
Giemsa staining
SKBr3 cells untreated or treated with paclitaxel or obtained from the shake-off experiments were cytospun on slides. After air drying, slides were fixed in cold methanol for 10 min and then subjected to Giemsa staining according to our previous report (Panditax et al., 1994) .
Mechanical shake-off experiment
Asynchronous SKBr3 cells growing in 175-cm 2 culture flasks were treated with 20 nm paclitaxel for 24 h in 50 ml of culture medium. Fractions (detached or shake-off) containing mitotic cells were obtained by shaking the flask firmly for 1 min. Cell culture media were then pipetted as described previously (Boonstra et al., 1981) . Cells that remained adherent to culture flasks were designated as attached fractions.
Transient transfection
SKBr3 cells grown in 60 mm dishes were transfected with p70S6K wild-type and mutants constructs according to a previously described procedures (Le et al., 2001) .
Statistical analysis
The two-tailed Student's t-test was used to compare two different groups. Values with Po0.05 were considered significant.
